Pipex Pharmaceuticals Acquires Late-Stage Oral Phase II Candidate For Rheumatoid Arthritis

 23.08.2008 10:18   medicalnewstoday.com

Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that it has acquired an oral, once-daily candidate for the treatment of rheumatoid arthritis (RA) which has completed a 160 patient, multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial for the treatment of rheumatoid arthritis (RA).

World Arthritis